Regeneron submits U.S. application for gMG drug cemdisiran
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) submitted a U.S. regulatory application for cemdisiran, an investigational treatment for generalized myasthenia gravis (gMG) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)